# Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients

> **NCT04217096** · PHASE4 · UNKNOWN · sponsor: **Fudan University** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **DRUG:** Paclitaxel liposome
- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT04217096
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-01
- **Primary completion:** 2022-09-30
- **Final completion:** 2023-03-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04217096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04217096, "Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04217096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*